Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer

Paavo Raittinen*, Kati Niemistö, Erika Pennanen, Heimo Syvälä, Seppo Auriola, Jarno Riikonen, Terho Lehtimäki, Pauliina Ilmonen, Teemu Murtola

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

39 Downloads (Pure)


Prostate cancer patients using cholesterol-lowering statins have 30% lower risk of prostate cancer death compared to non-users. The effect is attributed to the inhibition of the mevalonate pathway in prostate cancer cells. Moreover, statin use causes lipoprotein metabolism changes in the serum. Statin effect on serum or intraprostatic lipidome profiles in prostate cancer patients has not been explored. We studied changes in the serum metabolomic and prostatic tissue lipidome after high-dose 80 mg atorvastatin intervention to expose biological mechanisms causing the observed survival benefit. Our randomized, double-blind, placebo-controlled clinical trial consisted of 103 Finnish men with prostate cancer. We observed clear difference in post-intervention serum lipoprotein lipid profiles between the study arms (median classification error 11.7%). The atorvastatin effect on intraprostatic lipid profile was not as clear (median classification error 44.7%), although slightly differing lipid profiles by treatment arm was observed, which became more pronounced in men who used atorvastatin above the median of 27 days (statin group median classification error 27.2%). Atorvastatin lowers lipids important for adaptation for hypoxic microenvironment in the prostate suggesting that prostate cancer cell survival benefit associated with statin use might be mediated by both, local and systemic, lipidomic/metabolomic profile changes.

Original languageEnglish
Article number12016
Number of pages10
JournalScientific Reports
Issue number1
Publication statusPublished - 1 Dec 2020
MoE publication typeA1 Journal article-refereed

Fingerprint Dive into the research topics of 'Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer'. Together they form a unique fingerprint.

Cite this